Ro vs Willow
Ro costs $150 less a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Ro
Best for: knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC
Visit Ro →
Willow
Best for: seeing what it charges before you answer any medical questions
Visit Willow →If you are choosing between Ro and Willow, the first difference is cost: Ro is $150 a month cheaper at the entry price. Ro leads our six-part score, 6.7 to 6.6.
Ro vs Willow price
Ro is the cheaper way in: $149 a month against $299 a month at Willow. That is $150 less each month (50% lower), or about $1,800 over a year of treatment.
Medications and formats
Ro and Willow do not overlap on medication; only Ro lists orforglipron; only Willow lists semaglutide and tirzepatide.
On format, Ro prices brand-name pens, while Willow prices compounded injections.
If you want the FDA-approved brand rather than a compounded version, Ro is the only one of the two with a brand-name price.
Where each one treats patients
Neither Ro nor Willow publishes the states it serves, so enter your state at the very start of each sign-up.
Pricing
Ro
Additional membership fees apply
Willow
What each price covers
Both prices cover the clinician visit.
Ro's price also covers lab work and coaching, which Willow does not claim.
Willow's price also covers the medication itself and shipping, which Ro does not claim.
Ro is silent on shipping.
Willow is silent on lab work and coaching.
That matters most for the drug: unless Ro confirms otherwise, budget for medication on top of its listed price.
Ro
Covered by the monthly price
Medication
Charged on top
Clinician visits
In the price
Shipping
Not stated
Lab work
In the price
Coaching
In the price
Willow
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, Ro scores 6.7 and Willow 6.6 out of 10.
Ro is stronger on value (5.0 vs 3.0) and trust & safety (8.0 vs 6.5).
Willow is stronger on effectiveness (10.0 vs 8.0) and support (7.0 vs 5.5).
User experience and accessibility are within half a point.
Ro
6.7/10
Willow
6.6/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
Neither Ro nor Willow has an FDA warning letter on record with us.
Features & Coverage
| Feature | Ro | Willow |
|---|---|---|
| Starting Price | ✓$149/mo | $299/mo |
| Features | ✓7 features | 3 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | None | None |
About Ro
Foundayo (orforglipron), the new oral GLP-1 from Eli Lilly, joined Ro on April 9 2026 at $149/month for the lowest dose, membership on top. Beside it sit compounded semaglutide and the brand-name pair, Zepbound and Wegovy. No obesity care formulary in the category is more comprehensive. In the US, only a handful of direct-to-patient telehealth companies are larger.
Read our full Ro review →About Willow
Tablets and injections are both on offer at Willow, a telehealth seller of compounded GLP-1 medications.
Read our full Willow review →Pros & Cons
Ro
What we like
- Orforglipron costs $149 a month, close to the $149 median for brand-name orforglipron across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes clinician visits, lab work and coaching
- Names Roman Health Pharmacy LLC as the pharmacy that fills its prescriptions, which most sellers do not
- We found no FDA warning letters issued to Ro
Watch-outs
- Not included in the monthly price: medication
- Confirm it serves your state before you start the intake
Willow
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
- We found no FDA warning letters issued to Willow
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Willow is where we would start, above all for seeing what it charges before you answer any medical questions. Ro undercuts it by $150 a month, so if the monthly bill is what decides it, Ro is the pick. Ro fits better if knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC is your priority.
Choose Ro if…
You want knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC and an opening price near $149 a month.
Choose Willow if…
You want seeing what it charges before you answer any medical questions and an opening price near $299 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HealthRX
Compounded semaglutide at $133/month
From $133/mo
Get started →RNK Health
An oral route if you will not self-inject
From $197/mo
Get started →He & She MD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →Ro vs Willow: FAQ
Close alternatives to Ro and Willow
- Ro vs Amazon One Medical
- Ro vs LillyDirect Foundayo
- Ro vs GoodRx
- Ro vs Found
- Willow vs Remedy Meds
- Willow vs Apex MD
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.